JP2008500373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008500373A5 JP2008500373A5 JP2007515450A JP2007515450A JP2008500373A5 JP 2008500373 A5 JP2008500373 A5 JP 2008500373A5 JP 2007515450 A JP2007515450 A JP 2007515450A JP 2007515450 A JP2007515450 A JP 2007515450A JP 2008500373 A5 JP2008500373 A5 JP 2008500373A5
- Authority
- JP
- Japan
- Prior art keywords
- myostatin
- preparation
- protein
- amino acids
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 19
- 108010056852 Myostatin Proteins 0.000 claims 19
- 238000002360 preparation method Methods 0.000 claims 14
- 239000005557 antagonist Substances 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 239000003153 chemical reaction reagent Substances 0.000 claims 5
- 102100034135 Activin receptor type-1C Human genes 0.000 claims 4
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 claims 4
- 101000799193 Homo sapiens Activin receptor type-1C Proteins 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102100034134 Activin receptor type-1B Human genes 0.000 claims 2
- 102100025745 Cerberus Human genes 0.000 claims 2
- 101710010675 Cerberus Proteins 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 2
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 claims 2
- 210000000577 adipose tissue Anatomy 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims 1
- 241000202252 Cerberus Species 0.000 claims 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 1
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 claims 1
- 101000914195 Homo sapiens Cerberus Proteins 0.000 claims 1
- 101000912351 Homo sapiens DAN domain family member 5 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108010085220 Multiprotein Complexes Proteins 0.000 claims 1
- 102000007474 Multiprotein Complexes Human genes 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 108010023082 activin A Proteins 0.000 claims 1
- 230000009815 adipogenic differentiation Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 102000052506 human DAND5 Human genes 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000003473 lipid group Chemical group 0.000 claims 1
- 230000004807 localization Effects 0.000 claims 1
- 210000000663 muscle cell Anatomy 0.000 claims 1
- 230000037257 muscle growth Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229920002704 polyhistidine Polymers 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000003571 reporter gene assay Methods 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57506204P | 2004-05-27 | 2004-05-27 | |
| PCT/US2005/018928 WO2005115439A2 (en) | 2004-05-27 | 2005-05-27 | Cerberus/coco derivatives and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008500373A JP2008500373A (ja) | 2008-01-10 |
| JP2008500373A5 true JP2008500373A5 (enExample) | 2008-07-17 |
Family
ID=35451405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007515450A Pending JP2008500373A (ja) | 2004-05-27 | 2005-05-27 | ケルベロス（Ｃｅｒｂｅｒｕｓ）／ココ（Ｃｏｃｏ）誘導体およびそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20100183695A1 (enExample) |
| EP (1) | EP1755648A2 (enExample) |
| JP (1) | JP2008500373A (enExample) |
| KR (1) | KR20070026650A (enExample) |
| AU (1) | AU2005247508A1 (enExample) |
| CA (1) | CA2567810A1 (enExample) |
| IL (1) | IL179602A0 (enExample) |
| WO (1) | WO2005115439A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9045553B2 (en) * | 2004-05-27 | 2015-06-02 | Acceleron Pharma, Inc. | Cerberus/Coco derivatives and uses thereof |
| WO2007123391A1 (en) | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
| WO2008018795A1 (en) | 2006-08-11 | 2008-02-14 | Prosensa Technologies B.V. | Methods and means for treating dna repeat instability associated genetic disorders |
| WO2008073351A2 (en) * | 2006-12-08 | 2008-06-19 | Acceleron Pharma Inc. | Uses of cerberus, coco and derivatives thereof |
| CA3039330C (en) * | 2007-02-09 | 2021-11-09 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for promoting bone growth in cancer patients |
| US20100233137A1 (en) * | 2007-02-27 | 2010-09-16 | Lanx, Inc. | Compositions and Methods for Modification of Target Cells and to Their Uses Thereof |
| WO2008151119A2 (en) * | 2007-06-01 | 2008-12-11 | Lanx, Llc | Compositions and methods for use of scar tissue in repair of weight bearing surfaces |
| USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
| PT2203173E (pt) | 2007-10-26 | 2016-03-15 | Academisch Ziekenhuis Leiden | Resumo |
| WO2009105606A1 (en) * | 2008-02-21 | 2009-08-27 | Lanx, Llc | Compositions and methods for use of scar tissue in repair of weight bearing surfaces |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| US9149319B2 (en) * | 2008-09-23 | 2015-10-06 | Lanx, Llc | Methods and compositions for stabilization of a vertebra |
| NZ595955A (en) | 2009-04-24 | 2012-10-26 | Prosensa Technologies Bv | Oligonucleotide comprising an inosine for treating dmd |
| CN102482339B (zh) | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
| WO2010148010A1 (en) * | 2009-06-15 | 2010-12-23 | 4S3 Bioscience Inc. | Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularih 1 (mtm1) polypeptides |
| CA2779472C (en) | 2009-11-03 | 2021-03-16 | Acceleron Pharma Inc. | The use of a composition comprising an activin type iib receptor polypeptide in the treatment of fatty liver disease |
| DE102010052941A1 (de) * | 2010-11-18 | 2012-05-24 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Therapeutisches Protein |
| NZ627896A (en) | 2012-01-27 | 2016-11-25 | Biomarin Technologies B V | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| CA2911514A1 (en) | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| EP3741375A1 (en) * | 2014-07-17 | 2020-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating neuromuscular junction-related diseases |
| JP6706617B2 (ja) | 2014-11-06 | 2020-06-10 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
| RS62330B1 (sr) | 2015-09-15 | 2021-10-29 | Scholar Rock Inc | Antitela pro/latentnog miostatina i njihova upotreba |
| US10287345B2 (en) | 2016-01-08 | 2019-05-14 | Scholar Rock, Inc. | Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies |
| EP3439741A4 (en) | 2016-04-06 | 2020-05-06 | Acceleron Pharma Inc. | ALK7 ANTAGONISTS AND USES THEREOF |
| KR20210082548A (ko) | 2016-06-13 | 2021-07-05 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
| SI3565592T1 (sl) | 2017-01-06 | 2023-05-31 | Scholar Rock, Inc. | Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina |
| CN109758616B (zh) * | 2019-03-05 | 2021-11-19 | 中国医学科学院北京协和医院 | 一种新型促进骨再生材料及其制备方法 |
| KR20250122524A (ko) | 2022-12-22 | 2025-08-13 | 스칼러 락, 인크. | 미오스타틴 활성화의 선택적이고 강력한 억제 항체 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6133232A (en) * | 1996-06-20 | 2000-10-17 | The Regents Of The University Of California | Endoderm, cardiac and neural inducing factors |
| WO1998034951A1 (en) | 1997-02-11 | 1998-08-13 | Amrad Operations Pty. Ltd. | A new cytokine family and uses thereof |
| JP4062551B2 (ja) * | 1997-04-29 | 2008-03-19 | リジェネロン ファーマシューティカルズ，インコーポレイテッド | ヒトケルベロスタンパク質 |
| US5935852A (en) | 1997-07-03 | 1999-08-10 | Genetics Institute, Inc. | DNA molecules encoding mammalian cerberus-like proteins |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| CA2319703C (en) | 1998-02-05 | 2005-09-20 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| WO2000055193A2 (en) | 1999-03-12 | 2000-09-21 | Regeneron Pharmaceuticals, Inc. | Human dan/cerberus related protein 6 (dcr6) |
| WO2002032929A2 (en) | 2000-10-19 | 2002-04-25 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the cer1 gene |
| AU2002243495A1 (en) | 2001-01-12 | 2002-07-24 | University Of Medicine And Dentistry Of New Jersey | Bone morphogenetic protein-2 in the treatment and diagnosis of cancer |
| EP1383867A2 (en) | 2001-03-23 | 2004-01-28 | Axordia Limited | Stem cell differentiation |
| WO2002078516A2 (en) | 2001-03-30 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| GB0111004D0 (en) | 2001-05-04 | 2001-06-27 | Univ Sheffield | Screening method |
| US6513196B2 (en) | 2001-06-22 | 2003-02-04 | Maytag Corporation | Top cover hinge and method for using same |
| CN1161875C (zh) | 2001-07-01 | 2004-08-11 | 周符明 | 开关稳功率电源 |
| GB0118223D0 (en) | 2001-07-26 | 2001-09-19 | Univ Sheffield | Stem loop RNA |
| CN1685055A (zh) | 2001-10-31 | 2005-10-19 | 爱尔康公司 | 骨形态发生蛋白(bmp)、bmp受体和bmp结合蛋白及它们在诊断和治疗青光眼中的用途 |
| GB0130738D0 (en) | 2001-12-21 | 2002-02-06 | Serono Internat S A | Protein |
| US20030134790A1 (en) | 2002-01-11 | 2003-07-17 | University Of Medicine And Dentistry Of New Jersey | Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer |
| MXPA04008149A (es) * | 2002-02-21 | 2005-06-17 | Wyeth Corp | Proteinas que contienen dominios de folistatina. |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| AU2003276430A1 (en) | 2002-06-14 | 2003-12-31 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| WO2003106654A2 (en) | 2002-06-14 | 2003-12-24 | Diversa Corporation | Xylanases, nucleic adics encoding them and methods for making and using them |
| EP2272864A3 (en) * | 2002-12-20 | 2011-02-16 | Amgen Inc. | Binding agents which inhibit myostatin |
| WO2004074460A2 (en) | 2003-02-19 | 2004-09-02 | The Rockefeller University | Nucleotide and protein sequences of coc genes and methods based thereon |
-
2005
- 2005-05-27 WO PCT/US2005/018928 patent/WO2005115439A2/en not_active Ceased
- 2005-05-27 KR KR1020067027257A patent/KR20070026650A/ko not_active Withdrawn
- 2005-05-27 AU AU2005247508A patent/AU2005247508A1/en not_active Abandoned
- 2005-05-27 US US11/597,182 patent/US20100183695A1/en not_active Abandoned
- 2005-05-27 CA CA002567810A patent/CA2567810A1/en not_active Abandoned
- 2005-05-27 EP EP05780089A patent/EP1755648A2/en not_active Withdrawn
- 2005-05-27 JP JP2007515450A patent/JP2008500373A/ja active Pending
- 2005-05-27 US US11/140,024 patent/US7316998B2/en not_active Expired - Lifetime
-
2006
- 2006-11-27 IL IL179602A patent/IL179602A0/en unknown
-
2007
- 2007-08-20 US US11/894,289 patent/US7981857B2/en active Active
-
2012
- 2012-06-26 US US13/533,733 patent/US20130029908A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008500373A5 (enExample) | ||
| CN112292144B (zh) | 激活素受体iib型变体及其使用方法 | |
| US10730936B2 (en) | Engineered anti-TGF-β antibodies and antigen-binding fragments | |
| ES2361269T3 (es) | Anticuerpos especificos de tgf beta 1. | |
| US11090361B2 (en) | Activin receptor type IIa variants and methods of use thereof | |
| JP7776461B2 (ja) | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 | |
| CA3009650A1 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| EP2305715A2 (en) | Monoclonal antibody to osteoprotegerin binding protein | |
| JP7250706B2 (ja) | 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法 | |
| US11484573B2 (en) | Activin receptor type IIa variants and methods of use thereof | |
| AU2012205384B2 (en) | IL-27 antagonists for treating inflammatory diseases | |
| RU2770209C2 (ru) | Терапевтические антитела против лиганда cd40 | |
| EA021425B1 (ru) | Мутанты fgf21 и их применение | |
| CN110177564A (zh) | 多价的调节t细胞调节剂 | |
| JP2009545313A5 (enExample) | ||
| CN105612173A (zh) | 用于治疗心力衰竭的环状apelin衍生物 | |
| JP2018538356A (ja) | 組織修復のための二重特異性治療用タンパク質 | |
| TW201425339A (zh) | 用於治療心臟衰竭之合成線狀愛帕琳（ａｐｅｌｉｎ）模擬物 | |
| US12329801B2 (en) | Regenerative polypeptides and uses thereof | |
| CN118159557A (zh) | Sars-cov-2棘蛋白特异性抗体及其用途 | |
| AU2014305658A1 (en) | An antibody therapy for amyloid beta disease | |
| EP3355908A1 (en) | Treatment of bile acid disorders | |
| AU2007332819A1 (en) | Uses of cerberus, coco and derivatives thereof | |
| CN100413888C (zh) | 可溶性多肽 | |
| CN107531798A (zh) | Pcsk9的抑制剂用于脂蛋白代谢病症的治疗 |